Nuwellis Q4 revenue rises on US console growth

Reuters03-10

Nuwellis Q4 revenue rises on US console growth

Overview

Medical technology firm's Q4 revenue grew 4% yr/yr, driven by U.S. console sales
Gross margin improved to 68.2% from 58.4% in prior-year quarter
Company announced $5 mln private placement and Rendiatech acquisition

Outlook

Nuwellis aims to integrate Rendiatech acquisition and expand cardiorenal portfolio in 2026
Company plans to progress development of Vivian, a pediatric solution, in 2026
Nuwellis focuses on driving consistent commercial execution and deeper utilization in 2026

Result Drivers

CONSOLE SALES - 208% increase in U.S. console sales drove Q4 revenue growth
GROSS MARGIN IMPROVEMENT - Gross margin rose to 68.2% due to improved pricing and product mix
HEART FAILURE AND PEDIATRICS - Heart Failure revenue increased 48% and Pediatrics increased 16% in Q4

Company press release: ID:nGNX77jFp2

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Sales	Beat	$2.42 mln	$2.31 mln (1 Analyst)
Q4 EPS		-$1.50
Q4 Net Income		-$2.42 mln
Q4 Gross Profit		$1.65 mln
Q4 Income from Operations		-$2.44 mln
Q4 Pretax Profit		-$2.42 mln

Analyst Coverage

The one available analyst rating on the shares is "hold"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618693004?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618693004","market":"nz","top_or_hot":-1,"title":"Nuwellis Q4 revenue rises on US console growth","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Nuwellis Q4 revenue rises on US console growth</title></head><body><p><span>Overview</span></p><ul><li><p>Medical technology firm's Q4 revenue grew 4% yr/yr, driven by U.S. console sales</p></li><li><p>Gross margin improved to 68.2% from 58.4% in prior-year quarter</p></li><li><p>Company announced $5 mln private placement and Rendiatech acquisition</p></li></ul><p><span>Outlook</span></p><ul><li><p>Nuwellis aims to integrate Rendiatech acquisition and expand cardiorenal portfolio in 2026</p></li><li><p>Company plans to progress development of Vivian, a pediatric solution, in 2026</p></li><li><p>Nuwellis focuses on driving consistent commercial execution and deeper utilization in 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CONSOLE SALES - 208% increase in U.S. console sales drove Q4 revenue growth</p></li><li><p>GROSS MARGIN IMPROVEMENT - Gross margin rose to 68.2% due to improved pricing and product mix</p></li><li><p>HEART FAILURE AND PEDIATRICS - Heart Failure revenue increased 48% and Pediatrics increased 16% in Q4</p></li></ul><p>Company press release: <span>ID:nGNX77jFp2</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td><p>Beat</p></td><td><p>$2.42 mln</p></td><td><p>$2.31 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$1.50</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$2.42 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$1.65 mln</p></td><td></td></tr><tr><td><p>Q4 Income from Operations</p></td><td></td><td><p>-$2.44 mln</p></td><td></td></tr><tr><td><p>Q4 Pretax Profit</p></td><td></td><td><p>-$2.42 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuwellis Q4 revenue rises on US console growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuwellis Q4 revenue rises on US console growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Nuwellis Q4 revenue rises on US console growth</title></head><body><p><span>Overview</span></p><ul><li><p>Medical technology firm's Q4 revenue grew 4% yr/yr, driven by U.S. console sales</p></li><li><p>Gross margin improved to 68.2% from 58.4% in prior-year quarter</p></li><li><p>Company announced $5 mln private placement and Rendiatech acquisition</p></li></ul><p><span>Outlook</span></p><ul><li><p>Nuwellis aims to integrate Rendiatech acquisition and expand cardiorenal portfolio in 2026</p></li><li><p>Company plans to progress development of Vivian, a pediatric solution, in 2026</p></li><li><p>Nuwellis focuses on driving consistent commercial execution and deeper utilization in 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CONSOLE SALES - 208% increase in U.S. console sales drove Q4 revenue growth</p></li><li><p>GROSS MARGIN IMPROVEMENT - Gross margin rose to 68.2% due to improved pricing and product mix</p></li><li><p>HEART FAILURE AND PEDIATRICS - Heart Failure revenue increased 48% and Pediatrics increased 16% in Q4</p></li></ul><p>Company press release: <span>ID:nGNX77jFp2</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td><p>Beat</p></td><td><p>$2.42 mln</p></td><td><p>$2.31 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$1.50</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$2.42 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$1.65 mln</p></td><td></td></tr><tr><td><p>Q4 Income from Operations</p></td><td></td><td><p>-$2.44 mln</p></td><td></td></tr><tr><td><p>Q4 Pretax Profit</p></td><td></td><td><p>-$2.42 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMI","symbol_name":"康明斯","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL1N3ZY0IJ:1","article_id":"2618693004","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618693004","pubTimestamp":1773145432,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nuwellis Q4 revenue rises on US console growthOverviewMedical technology firm's Q4 revenue grew 4% yr/yr, driven by U.S. console salesGross margin improved to 68.2% from 58.4% in prior-year quarterCom","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMI":"康明斯","BK4567":"ESG概念","BK4082":"医疗保健设备","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","NUWE":"Nuwellis, Inc.","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4588":"碎股","BK4149":"建筑机械与重型卡车","BK4585":"ETF&股票定投概念"},"translate_title":"Nuwellis第四季度收入因美国游戏机增长而增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMI":0.9,"NUWE":0.9},"content_text":"Nuwellis Q4 revenue rises on US console growthOverviewMedical technology firm's Q4 revenue grew 4% yr/yr, driven by U.S. console salesGross margin improved to 68.2% from 58.4% in prior-year quarterCompany announced $5 mln private placement and Rendiatech acquisitionOutlookNuwellis aims to integrate Rendiatech acquisition and expand cardiorenal portfolio in 2026Company plans to progress development of Vivian, a pediatric solution, in 2026Nuwellis focuses on driving consistent commercial execution and deeper utilization in 2026Result DriversCONSOLE SALES - 208% increase in U.S. console sales drove Q4 revenue growthGROSS MARGIN IMPROVEMENT - Gross margin rose to 68.2% due to improved pricing and product mixHEART FAILURE AND PEDIATRICS - Heart Failure revenue increased 48% and Pediatrics increased 16% in Q4Company press release: ID:nGNX77jFp2Key DetailsMetricBeat/MissActualConsensus EstimateQ4 SalesBeat$2.42 mln$2.31 mln (1 Analyst)Q4 EPS-$1.50Q4 Net Income-$2.42 mlnQ4 Gross Profit$1.65 mlnQ4 Income from Operations-$2.44 mlnQ4 Pretax Profit-$2.42 mlnAnalyst CoverageThe one available analyst rating on the shares is \"hold\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy.\"For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618693004","isCrawlerRequest":true}